<DOC>
	<DOCNO>NCT02401061</DOCNO>
	<brief_summary>Pre-clinical clinical evaluation show PRTX- 100 biological activity may lead improved platelet level decrease due immunological pathology PRTX-100 acceptable safety profile . In vivo treatment PRTX-100 show raise platelet count mouse model immune thrombocytopenia ( ITP ) . The primary objective study assess efficacy PRTX-100 term platelet response patient chronic/persistent ITP .</brief_summary>
	<brief_title>Open-Label , Dose Escalation Study PRTX-100 Adults With Persistent/Chronic Immune Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>1 . Willing able provide write informed consent prior initiation studyrelated procedure 2 . Male female ≥ 18 year age 3 . ITP persist ≥ 3 month . ITP must diagnose accordance The American Society Hematology 2011 Evidencebased Practice Guideline Immune Thrombocytopenia ( Neunert et al . 2011 ) International Consensus Report The Investigation Management Primary Immune Thrombocytopenia ( Provan et al . 2010 ) , locally applicable . 4 . Patients persistent/chronic ITP despite adequate therapy approve therapy eltrombopag romiplostim , one standard ITP treatment . Splenectomy consider one standard ITP treatment 5 . For subject receive ITP therapy : mean platelet count &lt; 30,000/μL , individual platelet count &gt; 35,000/μL ; subject receive constant dose permit treatment ITP : mean platelet count &lt; 50,000/μL , count great 55,000/μL . ( Note : The mean platelet count must determine base 2 platelet count include one obtain within ≤ 7 day first PRTX100 dose within ≤ 30 day first dose PRTX100 . ) 6 . If corticosteroid , dose &lt; 1 mg/kg prednisone per day equivalent stable ≥ 21 day prior first dose PRTX100 . Highdose pulse steroid therapy NOT allow within 60 day prior first dose PRTX100 . 7 . If receive eltrombopag romiplostim , dose must stable ≥ 21 day prior first dose PRTX100 8 . If steroidsparing adjunctive immunosuppression cyclosporine , azathioprine , mycophenolate , 6mercaptopurine , dose must stable ≥ 30 day prior first dose PRTX100 must expect remain stable study Day 29 , unless dose reduction require due toxicity . Treatment cytotoxic agent ( e.g . cyclophosphamide , vincristine ) allow within three month prior first dose PRTX 100 . 9 . Any prior treatment rituximab antiCD20 agent must &gt; 6 month prior first dose PRTX100 10 . If female , must pregnant ( pregnancy test perform locally female patient childbearing potential ) , must nurse must one following : Surgically sterile ( bilateral tubal ligation , hysterectomy ) Postmenopausal last natural menses &gt; 24 month prior Premenopausal use acceptable form birth control . Acceptable form birth control include : hormonal contraceptive ( implantable , oral , patch ) use ≥ 2 month prior screen double barrier method ( combination two following : intrauterine device [ IUD ] , male female condom spermicidal gel , diaphragm , sponge , cervical cap ) . All premenopausal female must negative urine serum pregnancy test screen Day 1 prior first PRTX100 treatment . 1 . Splenectomy ≤ 90 day prior first dose PRTX100 2 . Unstable coronary artery disease medical condition ( type 1 diabetes ) , Investigator 's opinion , might increase risk patient 3 . Evidence active infection require antibiotic therapy ≤ 14 day prior first dose PRTX 100 4 . Myelodysplastic syndrome . If clinically significant anemia pancytopenia exists , documentation bone marrow aspirate within 24 month prior first dose PRTX100 show evidence myelodysplasia require . 5 . Medical history vasculitis lupus erythematosus 6 . History treatment cancer within past two year basal cell squamous cell carcinoma skin treat curative intent 7 . Seropositive human immunodeficiency virus 8 . History acute/chronic hepatitis B C and/or carrier hepatitis B C ( positive hepatitis B surface antigen positive antihepatitis C antibody test ) 9 . History suggestive substance abuse 10 . Clinically significant abnormality screen laboratory test , include : Absolute neutrophil count &lt; 1.0 x 10^9/L Absolute lymphocyte count &lt; 0.8 x 10^9/L Hemoglobin &lt; 10 g/dL Alanine transaminase aspartate transaminase &gt; 2 x upper limit normal ( ULN ) Lactate dehydrogenase &gt; 3 x ULN Total Bilirubin &gt; 1.5 x ULN Serum creatinine level &gt; 1.6 mg/dL ( 0.14 mmol/L ) males 1.4 mg/dL ( 0.12 mmol/L ) females 11 . Treatment intravenous immunoglobulin ( IVIG ) ≤ 14 day prior first dose PRTX100 12 . Treatment antiRh D antigen agent ( e.g . WinRho® ) ≤ 14 day prior first dose PRTX 100 13 . Use investigational drug ≤ 30 day 5 halflives investigational drug ( whichever longer ) prior first dose PRTX100 14 . Not willing stay study site 4 hour PRTX100 infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>ITP</keyword>
	<keyword>Thrombocytopenia</keyword>
</DOC>